vs
Apellis Pharmaceuticals, Inc.（APLS）与全食超市（SMPL）财务数据对比。点击上方公司名可切换其他公司
全食超市的季度营收约是Apellis Pharmaceuticals, Inc.的1.7倍（$340.2M vs $199.9M），全食超市净利率更高（7.4% vs -29.5%，领先36.9%），全食超市同比增速更快（-0.3% vs -5.9%），全食超市自由现金流更多（$48.0M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 3.0%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
全食超市是总部位于美国得克萨斯州奥斯汀的跨国连锁超市，现为亚马逊全资旗下品牌。门店主打无氢化脂肪、人工色素、人工香精、防腐剂的天然食品，是美国农业部认证的有机食品零售商，以丰富的有机商品选择深受消费者欢迎。
APLS vs SMPL — 直观对比
营收规模更大
SMPL
是对方的1.7倍
$199.9M
营收增速更快
SMPL
高出5.6%
-5.9%
净利率更高
SMPL
高出36.9%
-29.5%
自由现金流更多
SMPL
多$62.3M
$-14.3M
两年增速更快
APLS
近两年复合增速
3.0%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $340.2M |
| 净利润 | $-59.0M | $25.3M |
| 毛利率 | — | 32.3% |
| 营业利润率 | -25.6% | 11.0% |
| 净利率 | -29.5% | 7.4% |
| 营收同比 | -5.9% | -0.3% |
| 净利润同比 | -62.2% | -33.7% |
| 每股收益（稀释后） | $-0.40 | $0.26 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSSMPL
| Q4 25 | $199.9M | $340.2M | ||
| Q3 25 | $458.6M | — | ||
| Q2 25 | $178.5M | $381.0M | ||
| Q1 25 | $166.8M | — | ||
| Q4 24 | $212.5M | $341.3M | ||
| Q3 24 | $196.8M | $375.7M | ||
| Q2 24 | $199.7M | $334.8M | ||
| Q1 24 | $172.3M | $312.2M |
净利润APLSSMPL
| Q4 25 | $-59.0M | $25.3M | ||
| Q3 25 | $215.7M | — | ||
| Q2 25 | $-42.2M | $41.1M | ||
| Q1 25 | $-92.2M | — | ||
| Q4 24 | $-36.4M | $38.1M | ||
| Q3 24 | $-57.4M | $29.3M | ||
| Q2 24 | $-37.7M | $41.3M | ||
| Q1 24 | $-66.4M | $33.1M |
毛利率APLSSMPL
| Q4 25 | — | 32.3% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 36.4% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 38.2% | ||
| Q3 24 | — | 38.8% | ||
| Q2 24 | — | 39.9% | ||
| Q1 24 | — | 37.4% |
营业利润率APLSSMPL
| Q4 25 | -25.6% | 11.0% | ||
| Q3 25 | 48.7% | — | ||
| Q2 25 | -18.6% | 15.6% | ||
| Q1 25 | -50.0% | — | ||
| Q4 24 | -12.3% | 16.0% | ||
| Q3 24 | -24.0% | 12.7% | ||
| Q2 24 | -14.7% | 17.6% | ||
| Q1 24 | -36.0% | 15.4% |
净利率APLSSMPL
| Q4 25 | -29.5% | 7.4% | ||
| Q3 25 | 47.0% | — | ||
| Q2 25 | -23.6% | 10.8% | ||
| Q1 25 | -55.3% | — | ||
| Q4 24 | -17.1% | 11.2% | ||
| Q3 24 | -29.2% | 7.8% | ||
| Q2 24 | -18.9% | 12.3% | ||
| Q1 24 | -38.5% | 10.6% |
每股收益（稀释后）APLSSMPL
| Q4 25 | $-0.40 | $0.26 | ||
| Q3 25 | $1.67 | — | ||
| Q2 25 | $-0.33 | $0.40 | ||
| Q1 25 | $-0.74 | — | ||
| Q4 24 | $-0.30 | $0.38 | ||
| Q3 24 | $-0.46 | $0.29 | ||
| Q2 24 | $-0.30 | $0.41 | ||
| Q1 24 | $-0.54 | $0.33 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $194.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $1.7B |
| 总资产 | $1.1B | $2.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSSMPL
| Q4 25 | $466.2M | $194.1M | ||
| Q3 25 | $479.2M | — | ||
| Q2 25 | $370.0M | $98.0M | ||
| Q1 25 | $358.4M | — | ||
| Q4 24 | $411.3M | $121.8M | ||
| Q3 24 | $396.9M | $132.5M | ||
| Q2 24 | $360.1M | $208.7M | ||
| Q1 24 | $325.9M | $135.9M |
总债务APLSSMPL
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $397.5M | ||
| Q2 24 | — | $237.7M | ||
| Q1 24 | $93.1M | $237.7M |
股东权益APLSSMPL
| Q4 25 | $370.1M | $1.7B | ||
| Q3 25 | $401.2M | — | ||
| Q2 25 | $156.3M | $1.8B | ||
| Q1 25 | $164.2M | — | ||
| Q4 24 | $228.5M | $1.8B | ||
| Q3 24 | $237.1M | $1.7B | ||
| Q2 24 | $264.3M | $1.7B | ||
| Q1 24 | $266.7M | $1.6B |
总资产APLSSMPL
| Q4 25 | $1.1B | $2.5B | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $821.4M | $2.4B | ||
| Q1 25 | $807.3M | — | ||
| Q4 24 | $885.1M | $2.4B | ||
| Q3 24 | $901.9M | $2.4B | ||
| Q2 24 | $904.5M | $2.2B | ||
| Q1 24 | $831.9M | $2.1B |
负债/权益比APLSSMPL
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.14× | ||
| Q1 24 | 0.35× | 0.14× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $50.1M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $48.0M |
| 自由现金流率自由现金流/营收 | -7.1% | 14.1% |
| 资本支出强度资本支出/营收 | 0.1% | 0.6% |
| 现金转化率经营现金流/净利润 | — | 1.98× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $223.6M |
8季度趋势，按日历期对齐
经营现金流APLSSMPL
| Q4 25 | $-14.2M | $50.1M | ||
| Q3 25 | $108.5M | — | ||
| Q2 25 | $4.4M | $101.1M | ||
| Q1 25 | $-53.4M | — | ||
| Q4 24 | $19.4M | $32.0M | ||
| Q3 24 | $34.1M | $48.9M | ||
| Q2 24 | $-8.3M | $72.8M | ||
| Q1 24 | $-133.0M | $46.5M |
自由现金流APLSSMPL
| Q4 25 | $-14.3M | $48.0M | ||
| Q3 25 | $108.3M | — | ||
| Q2 25 | $4.4M | $98.9M | ||
| Q1 25 | $-53.4M | — | ||
| Q4 24 | $19.3M | $31.7M | ||
| Q3 24 | — | $45.0M | ||
| Q2 24 | $-8.4M | $72.0M | ||
| Q1 24 | $-133.3M | $46.1M |
自由现金流率APLSSMPL
| Q4 25 | -7.1% | 14.1% | ||
| Q3 25 | 23.6% | — | ||
| Q2 25 | 2.5% | 25.9% | ||
| Q1 25 | -32.0% | — | ||
| Q4 24 | 9.1% | 9.3% | ||
| Q3 24 | — | 12.0% | ||
| Q2 24 | -4.2% | 21.5% | ||
| Q1 24 | -77.3% | 14.8% |
资本支出强度APLSSMPL
| Q4 25 | 0.1% | 0.6% | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | 0.6% | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | 0.1% | ||
| Q3 24 | 0.0% | 1.0% | ||
| Q2 24 | 0.0% | 0.2% | ||
| Q1 24 | 0.2% | 0.1% |
现金转化率APLSSMPL
| Q4 25 | — | 1.98× | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | 2.46× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.84× | ||
| Q3 24 | — | 1.67× | ||
| Q2 24 | — | 1.76× | ||
| Q1 24 | — | 1.40× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
SMPL
| Quest | $211.4M | 62% |
| Atkins Domain | $79.7M | 23% |
| OWYN | $28.1M | 8% |
| Other | $20.9M | 6% |
